New trial
Feasibility Study Using FUS with Oral Etoposide in Pediatric Diffuse Midline Glioma
- Trial ID
- NCT05762419 on ClinicalTrials.gov
- Cancer type
- Glioma / Glioblastoma
- Published in
- New in Oncology - May 21, 2025
Columbia is assessing whether focused ultrasound can safely open the blood brain barrier to boost oral etoposide delivery in children with progressive diffuse midline glioma, potentially enhancing tumor uptake while reducing systemic side effects.
More in brain and CNS tumors
-
Trial result · Oct 15, 2026 · NCT04365374
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets -
Trial result · Oct 15, 2026 · NCT03946527
Lanreotide (somatostatin analog) shows disease stabilization in advanced PPGL in a Phase 2 preprint -
New trial · Oct 15, 2026 · NCT07831772
REMIND feasibility study tests a single maintenance IMRT fraction after temozolomide-based treatment in glioblastoma -
New trial · Oct 15, 2026 · NCT07664176
Phase 1 nivolumab plus focused ultrasound and microbubbles tests blood-brain barrier opening in recurrent pediatric brain tumors -
New trial · Oct 15, 2026 · NCT07831369
Phase 2 VISTA combines valproic acid, irinotecan, and simvastatin for recurrent malignant glioma